----
Current ValuationThe current P/E ratio is 32.27, within the reasonable range, cheaper than 23.75% of the time in the past 1 years, and the industry ranks 18/74, the industry Median --.
32.27xP/E
$13.84Stock price
$0.43Earnings per share
32.27xP/E
Stock price$13.84Earnings per share$0.43
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 29.19x
- Typical range
- 24.85x–32.73x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
09182736
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
CVSUSCVS Health | 23.15x | 393.80% | $113.20B |
LHUSLabcorp | 28.72x | 29.02% | $28.84B |
DGXUSQuest Diagnostics | 24.61x | 17.98% | $27.68B |
BTSGUSBrightSpring Health Services | 31.96x | 93.43% | $13.11B |
CHEUSChemed | 28.06x | 21.43% | $7.92B |
OPCHUSOption Care Health | 22.65x | 18.20% | $4.75B |
CRVLUSCorVel | 36.45x | -- | $4.20B |
GRDNUSGuardian Pharmacy Services | 38.44x | 56.67% | $2.53B |
ADUSUSAddus Homecare | 22.30x | 18.27% | $2.35B |
VMDUSViemed Healthcare | 24.80x | 11.71% | $359.55M |
INFUUSInfusystem | 32.27x | 37.64% | $275.65M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
